Abstract | CONTEXT: OBJECTIVE: We compared the endocrine effects of cortistatin-17 with those of somatostatin-14 in patients with acromegaly (ACRO) or prolactinoma (PRLOMA). Normal subjects (NS) were studied as control group. DESIGN: All subjects underwent the following tests: 1) saline, 2) somatostatin-14 (2.0 microg/kg.h iv, 0-120 min) and 3) cortistatin-17 (2.0 microg/kg.h iv, 0-120 min) infusion. RESULTS: Cortistatin-17 and somatostatin-14 inhibited GH secretion to the same extent in ACRO (P < 0.05) and NS (P < 0.01). Cortistatin-17 and somatostatin-14 inhibited PRL secretion in PRLOMA (P < 0.05), to some extent in ACRO (P value not significant), but not in NS. Insulin secretion was inhibited by both cortistatin-17 and somatostatin-14 to the same extent in all groups (P < 0.05). CONCLUSIONS: Cortistatin-17 and somatostatin-14 display the same effects on GH, PRL, and insulin secretion in patients with ACRO or PRLOMA.
|
Authors | S Grottoli, V Gasco, F Broglio, R Baldelli, F Ragazzoni, F Gallenca, A Mainolfi, F Prodam, G Muccioli, E Ghigo |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 91
Issue 4
Pg. 1595-9
(Apr 2006)
ISSN: 0021-972X [Print] United States |
PMID | 16449338
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- CORT protein, human
- Carrier Proteins
- Insulin
- Neuropeptides
- Human Growth Hormone
- Somatostatin
- Prolactin
- Glucose Oxidase
|
Topics |
- Acromegaly
(blood)
- Adult
- Aged
- Area Under Curve
- Blood Glucose
(metabolism)
- Body Mass Index
- Carrier Proteins
(adverse effects, pharmacology)
- Female
- Glucose Oxidase
(metabolism)
- Human Growth Hormone
(blood)
- Humans
- Insulin
(blood)
- Male
- Middle Aged
- Neuropeptides
(adverse effects, pharmacology)
- Pituitary Neoplasms
(blood)
- Prolactin
(blood)
- Prolactinoma
(blood)
- Somatostatin
(adverse effects, pharmacology)
|